A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects-Reference-Cited by-同舟云学术

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects

Published:2021-10-18 Issue: Volume: Page:1-9
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Liu Guangwen¹,Xu Zhongnan²,Yang Wei¹,Xue Jinling²,Wang Yanli¹,Liu Zhengzhi¹,Cui Yingzi¹,Qu Xinyao¹,Chang Tianying¹,Yu Shuang¹,Cheng Yang¹,Zhou Yannan¹,Chen Jiahui¹,Ren Qing¹,Wang Wanhua¹,Deng Qiaohuan³,Wang Zeyu¹³,Yang Haimiao¹

Affiliation:

1. Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China

2. Department of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China

3. Scientific Research Office, Changchun University of Chinese Medicine, Jilin, China

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1988567

Reference33 articles.

1. Global Cancer Incidence and Mortality Rates and Trends—An Update

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

4. The Distinctive Nature of HER2-Positive Breast Cancers

5. The EGFR family and its ligands in human cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects;BioDrugs;2022-05